Study Shows Gilead's Ranexa Reduces Angina Frequency in Chronic Angina Patients With Type 2 Diabetes - InvestingChannel

Study Shows Gilead’s Ranexa Reduces Angina Frequency in Chronic Angina Patients With Type 2 Diabetes

Gilead Sciences (NASDAQ: GILD) today announced data from the Phase

4 TERISA (Type 2 Diabetes Evaluation

of Ranolazine In

Subjects With Chronic Stable Angina)

study, which demonstrated that the addition of ranolazine to background

antianginal therapy in chronic angina patients with type 2 diabetes

significantly reduced the frequency of weekly angina episodes compared

to placebo and background antianginal therapy. Results were presented

today during a Late-Breaking Clinical Trial session at the American

College of Cardiology’s 62nd Annual Scientific Session

(ACC.13) in San Francisco and were published online ahead of print in

the Journal of the American College of Cardiology.

Ranexa® (ranolazine) is indicated for the treatment of

See full press release

Posted in: News, Guidance, Management, M